Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Regeneron and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab).

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...